TPP Nikola Tesla

Miller Law LLC and Safirstein Law LLC Announce Proposed Settlements in the Namenda Indirect Purchaser Antitrust Litigation

Retrieved on: 
Monday, December 5, 2022
Class Action Lawsuit, Professional Services, Legal, Summons, Court order, Forest Laboratories, Hearing, District court, Teva, Sun Pharma, AB, Merz, Upsher-Smith Laboratories, TPP Nikola Tesla, Generic, Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., Person, Court, Comment, Partnership, Merz Pharma, Actavis, Laboratory, Tablet, Indian Residential Schools Settlement Agreement, Generic drug, Insurance, Life insurance, Memantine

The proposed settlement with the Generic Defendants includes both consumers and third-party payors (entities such as employers or insurers with self-funded prescription drug plans).

Key Points: 
  • The proposed settlement with the Generic Defendants includes both consumers and third-party payors (entities such as employers or insurers with self-funded prescription drug plans).
  • The settlement with Teva includes the AB-rated generic versions of Namenda IR 5 or 10 mg tablets.
  • If you are a member of one or both classes, you may comment on or object to the proposed settlements.
  • You must object to the settlements by February 3, 2023, or request to be excluded from the class by February 3, 2023.

Miller Law LLC and Safirstein Law LLC Announce Proposed Settlements in the Namenda Indirect Purchaser Antitrust Litigation

Retrieved on: 
Monday, December 5, 2022
Summons, Court order, Settlement, Court, Forest Laboratories, Hearing, District court, Teva, Plaintiff, Sun Pharma, AB, Alzheimer's disease, Merz, Upsher-Smith Laboratories, TPP Nikola Tesla, Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., Person, Comment, Partnership, Merz Pharma, Actavis, Laboratory, Tablet, Tobacco Master Settlement Agreement, Inwood Laboratories, Inc. v. Ives Laboratories, Inc., Wockhardt, Generic drug, Insurance, Life insurance, Memantine

The proposed settlement with the Generic Defendants includes both consumers and third-party payors (entities such as employers or insurers with self-funded prescription drug plans).

Key Points: 
  • The proposed settlement with the Generic Defendants includes both consumers and third-party payors (entities such as employers or insurers with self-funded prescription drug plans).
  • The settlement with Teva includes the AB-rated generic versions of Namenda IR 5 or 10 mg tablets.
  • If you are a member of one or both classes, you may comment on or object to the proposed settlements.
  • You must object to the settlements by February 3, 2023,or request to be excluded from the class by February 3, 2023.

Miller Law LLC and Safirstein Law LLC Announce Proposed Settlements in the Namenda Indirect Purchaser Antitrust Litigation

Retrieved on: 
Thursday, December 1, 2022
Class Action Lawsuit, Professional Services, Legal, Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., Upsher-Smith Laboratories, Comment, Merz Pharma, Tablet, Court order, Generic, AB, Indian Residential Schools Settlement Agreement, Merz, Actavis, Sun Pharma, TPP Nikola Tesla, District court, Summons, Teva, Partnership, Court, Laboratory, Person, Forest Laboratories, Hearing, Generic drug, Insurance, Life insurance, Memantine

The proposed settlement with the Generic Defendants includes both consumers and third-party payors (entities such as employers or insurers with self-funded prescription drug plans).

Key Points: 
  • The proposed settlement with the Generic Defendants includes both consumers and third-party payors (entities such as employers or insurers with self-funded prescription drug plans).
  • The settlement with Teva includes the AB-rated generic versions of Namenda IR 5 or 10 mg tablets.
  • If you are a member of one or both classes, you may comment on or object to the proposed settlements.
  • You must object to the settlements by February 3, 2023, or request to be excluded from the class by February 3, 2023.

Lowey Dannenberg, P.C. and The Dugan Law Firm, APLC Announce Court's Certification of Class Action Involving Third-Party Payors' Payment or Reimbursement for Some or All of the Purchase Price of Generic Nexium (esomeprazole magnesium), Brand or Generic Di

Retrieved on: 
Friday, November 5, 2021
Nexium, Valsartan, Person, South African Class ES, City, Pharmacy, AB, Plasma protein binding, Insurance, MDL Information Systems, TPP Nikola Tesla, Judgement, Ranbaxy Laboratories, John Joseph Moakley United States Courthouse, Maryland Office of the Public Defender, Court, MDL, District, FDA, TPP, Generic drug, Health insurance, Pharmaceutical industry, Maple syrup

Your rights may be affected by a class action lawsuit regarding the price paid for generic Nexium, brand and generic Diovan, and brand and generic Valcyte by Third-Party Payors ("TPPs") filed against Defendants Sun Pharmaceutical Industries, Ltd. And Ranbaxy, Inc.

Key Points: 
  • Your rights may be affected by a class action lawsuit regarding the price paid for generic Nexium, brand and generic Diovan, and brand and generic Valcyte by Third-Party Payors ("TPPs") filed against Defendants Sun Pharmaceutical Industries, Ltd. And Ranbaxy, Inc.
  • The case name is In Re Ranbaxy Generic Drug Application Antitrust Litigation, MDL No.
  • You are a member of the Class(es) if you are a TPP and you purchased or provided reimbursement for prescription drugs as described as follows:
    Generic Nexium Nationwide Class.
  • Any changes to the date or location of the trial will be posted to the case website.